Browsing Tag
inherited retinal disease
3 posts
How the GARDian3 trial could define the next commercial frontier in ophthalmic gene therapy
Discover how Ocugen, Inc.’s GARDian3 trial could redefine the commercial future of ophthalmic gene therapy and what investors should watch next.
Spark Therapeutics’ Luxturna gains EU approval as first gene therapy for inherited retinal disease
In a significant breakthrough for treating inherited vision loss, Pennsylvania-based Spark Therapeutics has received European Commission (EC) approval…
Spark Therapeutics’ Luxturna nears FDA approval for gene therapy treating inherited blindness
In a significant development in gene therapy, Spark Therapeutics’ Luxturna (voretigene neparvovec) is on the verge of receiving…